Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter
– Liquidity position at $1.1 billion as of March 31, 2021 to support continued pipeline progress SAN DIEGO --(BUSINESS WIRE)--May 5, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021 .
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5
PARK CITY, Utah --(BUSINESS WIRE)--Apr. 28, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2021 financial results and provide a corporate update on Wednesday, May 5, 2021 , after the close of the U.S. financial markets.
View HTML
Toggle Summary Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter
- Significant pipeline progress with potentially first- or best-in-class drug candidates - Strong cash position of $1.1 billion as of December 31, 2020 SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial
View HTML
Toggle Summary Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23
SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2020 financial results and provide a corporate update on Tuesday, February 23, 2021 , after the close of the U.S. financial markets.
View HTML
Toggle Summary Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis
- Delivered compelling topline results from ADVISE Ph 2b trial evaluating etrasimod in atopic dermatitis; advancing into a Ph 3 registrational program   - Initiated etrasimod trials: ELEVATE UC 12 Ph 3, GLADIATOR UC and alopecia areata Ph 2   - Completed enrollment of CAPTIVATE Ph 2b trial
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9
SAN DIEGO , Nov. 2, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2020 financial results and provide a corporate update on Monday, November 9, 2020 , after the close of the U.S. financial markets. The Company will host a conference call and live
View HTML
Toggle Summary Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter
- Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, topline data expected Q4 2020   - Progressing first- or best-in-class drug candidates with liquidity position of ~$1.3bn as of June 30, 2020 SAN DIEGO , Aug. 5, 2020 /PRNewswire/ --  Arena Pharmaceuticals,
View HTML
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2020 Financial Results and Provide Corporate Update on August 5
SAN DIEGO , July 29, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2020 financial results and provide a corporate update on Wednesday, August 5, 2020 , after the close of the U.S. financial markets. The Company will host a question and answer
View HTML
Toggle Summary Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results
- Ongoing clinical programs remain on track with data readouts expected between 2020-21 - Progressing first- or best-in-class drug candidates with liquidity position of ~$1bn as of March 31, 2020 SAN DIEGO , May 7, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7
SAN DIEGO , April 30, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020 , after the close of the U.S. financial markets. The Company will host a question and answer session
View HTML